|
|
|
|
Office Locations:
|
40 10th Avenue, Floor 7
New York, NY 10014
Phone: 646-597-6980
Fax: 646-597-6998
| | |
|
|
|
|
|
Life Sciences & Healthcare
|
|
|
|
RTW Investments is an investment firm focused on investments in the biopharma space, primarily within gene therapy, oligos, cancer, and rare disease. Investments are made anywhere across a company's life cycle from pre-clinical to commercial stage assets. RTW invests across the capital structure and invests in both public and private companies.
|
|
|
|
|
Investment Firm Key
VC = Venture Capital
PE = Private Equity
A = Angel
I = Incubator
MB = Merchant Bank
VD = Venture Debt
FI = Family Investment Office
FOF = Fund of Funds
ED = Economic Development Office
TT = Technology Transfer Office
CVC = Corporate Venture Capital
SEC = Secondary Purchaser
HF = Hedge Fund/Mutual Fund
|
|
| COMPANY STAGE | REVENUE |
| Venture Capital | |
Seed Stage
(includes "pre-seed," or
concept stage) | No Revenue |
| Early Stage | Minimal
Revenue |
Growth Stage
(also called Mid-stage) | $2M-$7M |
Expansion Stage
(also called Late-stage) | $7M and greater |
| Private Equity | |
| Lower Middle Market | $10M-$249M |
| Middle Market | $250M-$499M |
| Upper Middle Market | $500M-$1B |
| Large Cap | >$1B |
|
|
|
|
|
|
|
| Name | |
| |
Title | |
|
| Alexandra Taracanova | |
PhD | |
Director of Investor Relations | |
| Alice Lee | |
JD | |
Chief Compliance Officer and Senior Counsel | |
| Brad Sitko | |
| |
Managing Director | |
| David Moore | |
| |
Controller | |
| Gotham Makker | |
MD | |
Head of Strategic Investments | |
|
|
|
|
Date
|
Name
|
State
|
Amount
|
Stage
|
11/05/2024
|
Evommune
|
CA
|
$115,000,000
|
Series C
|
10/17/2024
|
Aktis Oncology
|
MA
|
$175,000,000
|
Series B
|
08/01/2024
|
Jade Biosciences
|
MA
|
$80,000,000
|
Venture
|
06/13/2024
|
Santa Ana Bio
|
CA
|
$168,000,000
|
Series A and B
|
04/03/2024
|
Obsidian Therapeutics
|
MA
|
$160,500,000
|
Series C
|
02/13/2024
|
BioAge Labs
|
CA
|
$170,000,000
|
Series D
|
02/01/2024
|
Basking Biosciences
|
OH
|
$55,000,000
|
Series B
|
|
|
|
|
|
|
|
